HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools Register Now!
Market News Stocks News ETF News Crypto News

Calidi Biotherapeutics, Inc

Contributing Author

Recent Articles by Calidi Biotherapeutics, Inc

Nov-17
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 CLDI GlobeNewswire
Nov-13
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights CLDI GlobeNewswire
Nov-10
Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC CLDI GlobeNewswire
Nov-04
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting CLDI GlobeNewswire
Oct-30
Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting CLDI GlobeNewswire
Oct-22
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine CLDI GlobeNewswire
Sep-29
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston CLDI GlobeNewswire
Sep-02
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference CLDI GlobeNewswire
Aug-21
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option CLDI GlobeNewswire
Aug-20
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering CLDI GlobeNewswire
Aug-08
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights CLDI GlobeNewswire
Jul-29
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma CLDI GlobeNewswire
Jul-25
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 CLDI GlobeNewswire
Jul-22
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 CLDI GlobeNewswire
Jul-10
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment CLDI GlobeNewswire
Jul-09
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds CLDI GlobeNewswire
Jul-08
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment CLDI GlobeNewswire
Jun-27
Calidi Biotherapeutics Announces Shareholder Letter from CEO CLDI GlobeNewswire
Jun-02
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting CLDI GlobeNewswire
May-14
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights CLDI GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.